Research compounds
Adropin
ENHO gene product
Adropin is a small secreted peptide encoded by the energy homeostasis associated gene, involved in fuel selection, insulin sensitivity and endothelial function. It is an early-stage research target with no approved product.
Also known as: ENHO
- Status
- Adropin is a research compound and not approved by the FDA for human use.
- Evidence
- Preclinical. Evidence comes from animal or lab studies; effects in people are not established.
- Half-life
- Not established in humans.
- How it's taken
- Injection in the preclinical research setting
- Mechanism
- Metabolic (non-incretin)
How Adropin works
Adropin is expressed in liver and brain and regulates the balance between glucose and fatty acid oxidation, in part by modulating pyruvate dehydrogenase activity. It also promotes endothelial nitric oxide production. Circulating levels vary with diet and fall in obesity and insulin resistance.
What research has looked at
- Animal studies report improved glucose tolerance and insulin sensitivity with adropin administration.
- Its role in substrate selection — shifting fuel preference toward glucose — is mechanistically distinct from incretin and insulin-sensitising pathways.
- Low circulating adropin is consistently associated with metabolic syndrome and cardiovascular disease in human cohorts, making it a candidate biomarker.
Evidence level: Preclinical. Evidence comes from animal or lab studies; effects in people are not established. These are areas studied or reported, not promised effects.
Reported side effects and risks
- All the interventional evidence is from animals. There are no human trials of administered adropin for any indication. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy.
- Human data are observational associations, which cannot distinguish cause from consequence — low adropin may simply be a marker of metabolic dysfunction rather than a driver.
- Its receptor and full signalling pathway remain incompletely defined.
- Long-term consequences of manipulating fuel selection pharmacologically are unstudied.
Sources
- PubMed research on adropin ENHO fuel selection insulin sensitivity · NIH · National Library of Medicine
- DrugBank record for adropin · DrugBank
- Active clinical trials for adropin · U.S. National Library of Medicine
Track Adropin in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Adropin FAQ
What is Adropin?
Adropin is a small secreted peptide encoded by the energy homeostasis associated gene, involved in fuel selection, insulin sensitivity and endothelial function. It is an early-stage research target with no approved product.
How does Adropin work?
Adropin is expressed in liver and brain and regulates the balance between glucose and fatty acid oxidation, in part by modulating pyruvate dehydrogenase activity. It also promotes endothelial nitric oxide production. Circulating levels vary with diet and fall in obesity and insulin resistance.
Is Adropin FDA approved?
No. Adropin is a research compound and not approved by the FDA for human use. Evidence level: preclinical. Evidence comes from animal or lab studies; effects in people are not established.
How is Adropin taken?
Injection in the preclinical research setting.
What side effects have been reported with Adropin?
Reported in the sources: All the interventional evidence is from animals. There are no human trials of administered adropin for any indication. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy; Human data are observational associations, which cannot distinguish cause from consequence — low adropin may simply be a marker of metabolic dysfunction rather than a driver; Its receptor and full signalling pathway remain incompletely defined; Long-term consequences of manipulating fuel selection pharmacologically are unstudied.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.